Flexion Therapeutics (FLXN) Gets a Buy Rating from RBC Capital
RBC Capital analyst Randall Stanicky maintained a Buy rating on Flexion Therapeutics (FLXN) on November 4 and set a price target of $18.00. The company’s shares closed last Thursday at $11.74.
According to TipRanks.com, Stanicky ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.7% and a 34.7% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Aquestive Therapeutics, and Eagle Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Flexion Therapeutics with a $21.22 average price target, representing a 63.6% upside. In a report issued on November 4, Raymond James also maintained a Buy rating on the stock with a $18.00 price target.
See today’s analyst top recommended stocks >>
Based on Flexion Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $15.45 million and GAAP net loss of $32.62 million. In comparison, last year the company earned revenue of $16.95 million and had a GAAP net loss of $36.49 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.